Exhaled Breath Condensate Assessment in Stable Non-Cystic Fibrotic Bronchiectasis

July 7, 2022 updated by: Jin-Fu Xu, Shanghai Pulmonary Hospital, Shanghai, China

Exploring the Relationship Between pH of Exhaled Breath Condensate and Disease Severity as Well as Prognosis of Bronchiectasis

The measurement of markers in the expired breath condensate has proven to be a useful method for assessing and monitoring airway inflammation. The aim of this study is to determine the amounts of pH in the expired breath condensate of patients with bronchiectasis, and the relationship between pH and the severity of bronchiectasis.

Study Overview

Status

Completed

Conditions

Detailed Description

The aim of this study is to determine the amounts of pH in the expired breath condensate of patients with bronchiectasis, and the relationship between pH and the severity of bronchiectasis. Further clarify the link between EBC pH and the risk of future acute exacerbations, mortality and lung function decline through a one-year follow-up. Hoping to explore new validated biomarkers of the disease severity and progression in bronchiectasis. During the observation, EBC pH and other valid indicators will be measured when patients were enrolled.

Study Type

Observational

Enrollment (Actual)

121

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Shanghai
      • Shanghai, Shanghai, China, 200000
        • Shanghai Pulmonary Hospital , Tongji University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The age of all subjects are older than 18 . The diagnosis of bronchiectasis need reference to the guideline published by BTS in 2010 or 2012 China bronchiectasis expert consensus, clinical symptoms of cough and expectoration, with or without intermittent hemoptysis, and chest CT showed bronchiectasis there.All patients were clinically stable and had no evidence of exacerbation for at least 4 weeks before the study and had a negative history of allergy. None of patients had reversibility with inhaled salbutamol of 12% or more of predicted FEV1; All normal subjects had a negative history of allergy and normal lung function, they have no history of any lung disease (except for the history of pneumonia in the past time and small pulmonary nodules).

Description

Inclusion Criteria:Each subject must meet all of the following criteria to be included in this study:

  1. Willing to join in and sign the informed consent form.
  2. Age>18 years, the diagnosis of bronchiectasis need reference to the definition of "non-cystic fibrosis bronchiectasis guideline" published by British Thoracic Society in 2010 or 2012 China bronchiectasis expert consensus, clinical symptoms of cough and expectoration, with or without intermittent hemoptysis, and chest CT showed bronchiectasis there.
  3. All patients were clinically stable and had no evidence of infection or acute infective exacerbation (lower or upper respiratory tract) for at least 4 weeks before the study.
  4. Patients with good compliance: the subject must be willing to follow the test plan requirements in the research center to complete all the assessment of the visit.

Control Subjects:

  1. All normal subjects had a negative history of allergy (negative skin prick tests to common allergens);
  2. Normal lung function, and normal bronchial reactivity.
  3. No history of any lung disease (except for the history of pneumonia in the past time and small pulmonary nodules).

Exclusion Criteria:Subjects who meet any of the following criteria should be excluded from this study:

  1. Patients with a history of other respiratory diseases (cystic fibrosis, allergic bronchopulmonary aspergillosis, asthma, 1-antitrypsin deficiency, pulmonary tuberculosis, COPD, lung cancer, interstitial lung disease)and atopic diseases were excluded;
  2. Serious comorbidities (chronic renal failure, hepatic disease, etc.) ;
  3. Patients were on inhaled or oral mucolytics, or were receiving oxygen therapy or long-term oral antibiotics;
  4. Poor compliance or cannot cooperate judged by doctors;
  5. Participated in other clinical trials for nearly three months;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Exhaled breath condensate pH and the disease severity
Time Frame: One year
The Relationship between pH of exhaled breath condensate and disease severity of Bronchiectasis
One year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
BSI scores
Time Frame: 30 days
Assessment of the non-cystic fibrosis bronchiectasis severity according by the BSI score at the time of admission
30 days
SGRQ scores
Time Frame: 30 days
Assessment of the quality of life of non-cystic fibrosis bronchiectasis according by the St.George respiratory questionnaire at the time of admission
30 days
Lung function (FEV1 %, FVC %, FEV1/FVC %)
Time Frame: One year
Lung function will be measured at the time of admission
One year
Sputum and peripheral blood inflammatory index (including IL-6, IL-8, IL-1β, TNF-a)
Time Frame: One year
Sputum and peripheral blood inflammatory index will be assessed at the time of admission
One year
Sputum neutrophil cell
Time Frame: One year
Sputum neutrophil cell count and percentage will be assessed at the time of admission
One year
Sputum bacteriological evaluation
Time Frame: One year
Sputum bacteriological (pseudomonas aeruginosa and others) will be evaluated at the time of admission
One year
Blood gases parameters (PaO2, SaO2, PaCO2, pH)
Time Frame: 30 days
Blood gases will be assessed at the time of admission
30 days
Chest high-resolution computed tomography (CT)
Time Frame: One year
Chest high-resolution computed tomography (CT) will be evaluated at the time of admission
One year
Frequency of acute exacerbation during one year
Time Frame: 30 days
The number of acute exacerbation will be recorded by telephone follow-up monthly. The definition of acute exacerbation: if there are at least one symptoms (increased sputum volume or purulent sputum, increased dyspnea, increased cough, lung function decline, increased fatigue) or new symptoms (fever, pleurisy, hemoptysis, require antimicrobial therapy), then prompted acute exacerbation.
30 days
Time to first exacerbation during the one-year follow up
Time Frame: 30 days
The time to first exacerbation within one year after start of the study
30 days
The number of hospitalizations for exacerbation
Time Frame: 30 days
The number of hospitalizations for exacerbation within one year after start of the study
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 25, 2018

Primary Completion (Actual)

July 2, 2020

Study Completion (Actual)

July 2, 2020

Study Registration Dates

First Submitted

August 21, 2018

First Submitted That Met QC Criteria

August 21, 2018

First Posted (Actual)

August 22, 2018

Study Record Updates

Last Update Posted (Actual)

July 11, 2022

Last Update Submitted That Met QC Criteria

July 7, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 20180323

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.